Brii Biosciences Limited (Stock Code: 2137) has released updated Terms of Reference for its Nomination Committee, originally established on June 22, 2021, and now amended effective November 15, 2025.

The Nomination Committee is responsible for identifying and recommending director candidates, overseeing Board performance evaluations, and developing nomination guidelines. Its composition requires a majority of independent non-executive directors, including at least one of a different gender. The Board appoints one member as Chairman, who must also be either the Chairman of the Board or an independent non-executive director.

The revised Terms of Reference outline the Committee’s procedures, including at least one annual meeting and the requirement for minutes to be recorded in sufficient detail. The Committee is authorized to determine processes and criteria for selecting and evaluating candidates, and it may consult external advisors as needed. These updates align with regulatory requirements and are available on the websites of The Stock Exchange of Hong Kong Limited and the Company.